Materna Medical develops technologies addressing unmet needs in women's pelvic health, with a mission to transform the standard of care in OBGYN. Its first product, Milli, is a vaginal dilator originally launched as a wellness trainer in 2019 and cleared by the FDA in 2023 for over-the-counter sale. Milli outcomes have been studied in a post-market prospective virtual study called POMPOM. Materna's second product, Ellora, is an investigational device intended to reduce pelvic floor muscle injury during vaginal delivery and is being evaluated in the randomized EASE trial across 20 U.S. hospitals. The company recently raised $5 million in a B3 financing to support completion of the EASE trial readout, expand Milli channel access, and prepare Ellora's commercialization and manufacturing. Materna is headquartered in Mountain View, California.

Total raised

$45M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2026